The company retains a Market Volatility (i.e., Beta) of 0.3166, which attests to possible diversification benefits within a given portfolio. Let's try to break down what Healthequity's beta means in this case. As returns on the market increase, Healthequity returns are expected to increase less than the market. However, during the bear market, the loss on holding Healthequity will be expected to be smaller as well. Even though it is essential to pay attention to
Healthequity current price history, it is always good to be careful when utilizing equity current price movements. Our philosophy in determining any stock's
future performance is to check both, its past performance charts as well as the business as a whole, including all available
technical indicators. Healthequity exposes twenty-one different technical indicators, which can help you to evaluate its performance.
Healthequity has an expected return of -0.0049%. Please be advised to check out Healthequity
standard deviation, as well as the
relationship between the value at risk and
kurtosis to decide if
Healthequity performance from the past will be repeated at some point in the near future.
The successful prediction of HealthEquity
stock price could yield a significant profit to investors. But is it possible? The efficient-market hypothesis suggests that all published
stock prices of traded companies, such as HealthEquity, already reflect all publicly available information. This academic statement is a fundamental principle of many financial and investing theories used today. However, the typical investor usually disagrees with a 'textbook' version of this hypothesis and continually tries to find mispriced stocks to increase returns. We use internally-developed statistical techniques to arrive at
the intrinsic value of HealthEquity based on HealthEquity hews, social hype, general headline patterns, and widely used
predictive technical indicators. We also calculate exposure to HealthEquity's
market risk, different
technical and
fundamental indicators, relevant financial multiples and ratios, and then
comparing them to HealthEquity's related companies.
Use Technical Analysis to project HealthEquity expected Price
HealthEquity technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.
A focus of HealthEquity technical analysis is to determine if market prices reflect all relevant information impacting that market. A technical analyst looks at the history of HealthEquity trading pattern rather than external drivers such as economic, fundamental, or social events. It is believed that price action tends to repeat itself due to investors' collective, patterned behavior. Hence technical analysis focuses on identifiable price trends and conditions.
More Info...HealthEquity Gross Profit
HealthEquity Gross Profit growth is one of the most critical measures in evaluating the company. The Gross Profit growth rate is calculated simply by comparing HealthEquity previous period's values with its current period's values. Each time period you're measuring should be of equal lengths the increase or decrease, in a company's Gross Profit between two periods. Here we show HealthEquity Gross Profit growth over the last 10 years. Please check HealthEquity's
gross profit and other
fundamental indicators for more details.
A Deeper Analysis
This firm reported the last year's revenue of 778.03
M. Reported Net Loss for the year was (55.31
M) with profit before taxes, overhead, and interest of 423.71
M.
Cost of Revenue Breakdown
Healthequity Cost of Revenue yearly trend continues to be fairly stable with very little volatility. Cost of Revenue is likely to outpace its year average in 2022. Cost of Revenue usually refers to the aggregate cost of goods produced and sold and services rendered during the reporting period. Healthequity Cost of Revenue is fairly stable at the moment as compared to the past year. Healthequity reported Cost of Revenue of 332.85 Million in 2021
| 2015 | 54.19 Million |
| 2016 | 72.02 Million |
| 2017 | 94.61 Million |
| 2018 | 106.05 Million |
| 2019 | 206.08 Million |
| 2020 | 318.24 Million |
| 2021 | 332.85 Million |
| 2022 | 359.13 Million |
Our Healthequity analysis suggests possible reversion in October
Current Jensen Alpha is up to 0.09. Price may slide again. Healthequity currently demonstrates below-average downside deviation. It has Information Ratio of 0.06 and Jensen Alpha of 0.09. However, we advise investors to further question Healthequity expected returns to ensure all indicators are consistent with the current outlook about its relatively low value at risk. Understanding different market volatility trends often help investors to time the market. Properly using volatility indicators enable traders to measure Healthequity's stock risk against market volatility during both bullish and bearish trends. The higher level of volatility that comes with bear markets can directly impact Healthequity's stock price while adding stress to investors as they watch their shares' value plummet. This usually forces investors to rebalance their portfolios by buying different stocks as prices fall.
Our Final Perspective on Healthequity
When is the right time to buy or sell Healthequity? Buying stocks such as Healthequity isn't very hard. However, what challenging for most investors is doing it at the right time. Proper
market timing is something most people cannot do without
sophisticated tools, which help to isolate the right opportunities, deliver winning trades and diversify portfolios on a daily basis.
With a relatively neutral outlook on the current economy, it is better to hold off any trading of Healthequity as the current risk-reward utility is not appealing enough. Please use our equity advice module to run different scenarios to ensure your current risk level and investment horizon are fully reflective of your current investing preferences in regards to Healthequity.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectEditorial Staff
Raphi Shpitalnik is a Junior Member of Macroaxis Editorial Board. Raphael is a young entrepreneur who joined Macroaxis on a part-time basis at the beginning of the pandemic and eventually acquired a real taste for investing and fintech. He likes to analyze different equity instruments across a wide range of industries, focusing primarily on consumer products, sports, fintech, cannabis, and AI.
View Profile This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Raphi Shpitalnik do not own shares of HealthEquity. Please refer to our
Terms of Use for any information regarding our disclosure principles.
Would you like to provide feedback on the content of this article?
You can get in touch with us directly or send us a quick note via email to
editors@macroaxis.com